Feasibility was demonstrated with regard to recruitment, attrition, and treatment characteristics. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
The emphasis on benefits, rather than losses and difficulties, provides a new dimension to the way interventions for caregivers can be conceptualized and delivered. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Benefit-finding reduces depressive symptoms as well as global burden in the long-term and increases psychological well-being in the medium-term. 1 key finding →
Participants: 129 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A condensed protocol for communicating genetic risk for Alzheimer disease achieved similar educational results as an extended protocol in this study. 3 key findings →
Participants: 280 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
This study showed that some deficits on IC domains, as measured by simple screening tests and questions, can be associated with higher healthcare costs. 4 key findings →
Design: randomized controlled trial Participants: 442 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The Namaste Care Family program is dominant over usual care and, thus, cost-effective, although statistical uncertainty was considerable. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Higher baseline PP was significantly associated with increased Aβ (β = 0.078; p = 0.001), inferior temporal tau (β = 0.110; p = 0.032), and meta-temporal tau deposition (β = 0.116; p = 0.022). 4 key findings →
Design: cohort study Participants: 1,690 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In preclinical studies, it has demonstrated vascular protective and antioxidant effects, with emerging evidence suggesting potential neuroprotective properties. 2 key findings →
Design: randomized controlled trial Participants: 185 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Higher plasma carotenoid concentrations were associated with slower cognitive decline in APOE ε4 carriers, potentially mitigating genetic risk. 3 key findings →
Design: randomized controlled trial Participants: 442 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Occurrence of dementia during the 20 years of follow-up was 4%. 2 key findings →
Participants: 1,409 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Those individuals living alone, and those without any close social ties, both had an adjusted relative risk for developing dementia of 1.5 (95% CI 1.0-2.1 and 1.0-2.4, respectively). 2 key findings →
Participants: 176 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
It is unclear whether persons with diabetes are at increased risk for dementia, including Alzheimer's disease. 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Out of 3127 abstracts, 291 were included in the review. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A growing body of evidence suggests that adherence to the Mediterranean diet (MD) may protect against cognitive decline and dementia. 3 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The findings support the cross-cultural use of a relatively inexpensive odor identification test as an early biomarker of cognitive decline and AD dementia. 1 key finding →
Participants: 1,037 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
62/100
Based on analysis of prospective and nonprospective studies, NSAID exposure was associated with decreased risk of Alzheimer's disease. 3 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Non-motor symptoms (NMS) of Parkinson's disease can be predominant as the disease advances, thereby constituting a major source of disease burden for patients and caregivers. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A history of hypertension is related to a higher risk of MCI. 5 key findings →
Design: cohort study Participants: 918 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Long-term NSAID use may reduce the risk of AD, provided such use occurs well before the onset of dementia. 2 key findings →
Participants: 104 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Level of evidence Level V, systematic review. 3 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Potentially modifiable risk factors from early and midlife, with a cumulative detrimental effect on the brain, contribute to risk of dementia. 2 key findings →
Design: case-control study Participants: 310 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
There are cross-sectional evidences of an association between sleep disorders and cognitive impairment on older adults. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Mahjong and TC can preserve functioning or delay decline in certain cognitive domains, even in those with significant cognitive impairment. 2 key findings →
Design: open-label trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Hippocampal atrophy is associated with memory impairment and dementia and serves as a key biomarker in the preclinical stages of Alzheimer's disease. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Low vitamin B-12 status was associated with more rapid cognitive decline. 5 key findings →
Design: cohort study Participants: 1,648 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →